Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV

NEXT STORY
atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data
PREV STORY
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FIT Biotech Oy: FIT Biotech Oy’s Board of Directors has decided on the directed share issue without payment to the Company itself without payment

FIT Biotech OyCompany release December 27, 2017 at 4.30 pm FIT Biotech Oy's Board ...

author_avatar
NASDAQ Market News

Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)

author_avatar
NASDAQ Market News

Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment

author_avatar
NASDAQ Market News